<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/CINECAstyle.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-23T22:24:07Z</responseDate><request verb="GetRecord" identifier="oai:iris.unica.it:11584/266770" metadataPrefix="oai_dc">https://iris.unica.it/oai/request</request><GetRecord><record><header><identifier>oai:iris.unica.it:11584/266770</identifier><datestamp>2022-10-15T20:08:37Z</datestamp><setSpec>com_11584_207615</setSpec><setSpec>com_11584_111066</setSpec><setSpec>col_11584_265854</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>Identification &amp; characterization of natural and synthetic compounds as new anticancer agents</dc:title>
<dc:creator>TUVERI, ROSSANA</dc:creator>
<dc:subject>ajoene</dc:subject>
<dc:subject>cancer</dc:subject>
<dc:subject>cancro</dc:subject>
<dc:subject>chemioterapia</dc:subject>
<dc:subject>chemiotherapy</dc:subject>
<dc:subject>er stress</dc:subject>
<dc:subject>fenantroline</dc:subject>
<dc:subject>inhibitors</dc:subject>
<dc:subject>inibitori</dc:subject>
<dc:subject>phenanthroline</dc:subject>
<dc:subject>stress del re</dc:subject>
<dc:subject>vimentin</dc:subject>
<dc:subject>vimentina</dc:subject>
<dc:subject>Settore BIO/19 - Microbiologia Generale</dc:subject>
<dc:description>This thesis collects the work I have done during the three-year PhD Course. During my first&#xd;
year I have started a path that has allowed me to acquire different techniques devoted to set up&#xd;
and maintain primary cell cultures and cancer derived cell lines as well as to evaluate the&#xd;
cytotoxicity of potential novel synthetic inhibitors of human cancer cells. Part of the second and&#xd;
all the third year was spent at the University of Cape Town, South Africa, in the laboratory of&#xd;
prof. Ariel Katz under the supervision of proff. Roger Hunter and Catherine H. Kaschula&#xd;
investigating the anticancer activity of Z-ajoene, a garlic compound.&#xd;
Overall, the main aim of all the my research project was to identify and characterize natural or&#xd;
synthetic compounds as new antineoplastic agents. The results obtained are divided according&#xd;
to the research topics addressed:&#xd;
 Anticancer activity of new Phenanthroline compounds (Part I);&#xd;
 The garlic compound Z-ajoene as anticancer agents (Part II).&#xd;
Studies referring to the Part have been carried out at the University of Cagliari and were&#xd;
focalized on the evaluation of new Cu(II) -phenanthroline complexes as a potent antineoplastic&#xd;
agents against various solid and suspension tumours. The [Cu(1,10-phenanthrolin&#xd;
-5,6-diol)2(OH2)](ClO4)2 complex appears to be the most potent compound against human&#xd;
leukemia, prostate and lung cancer cell lines. The results obtained on the biological activity of&#xd;
this class of compounds, providing valuable information for the design of new anticancer drugs,&#xd;
have been published in the Journal of Inorganic Biochemistry (2014).&#xd;
As for the Part II of my research, I focused on the mechanisms underlying the anti-tumoral&#xd;
activity of garlic compound Z-ajoene on human triple –negative breast cancer cells. The results&#xd;
indicate that Z-ajoene localizes in the ER of MDA-MB-231 cells where it activates the unfolded&#xd;
protein response (UPR) and ER stress. These findings have been published in the Molecular&#xd;
Carcinogenesis journal (2015)&#xd;
Moreover, immunofluorescence studies support the concept that the Z-ajoene main target is a&#xd;
ER-resident chaperon protein (PDI), whose functional alteration may well be the cause of the&#xd;
cytotoxic effect. Another molecular target of Z-ajoene is the cytoskeleton protein Vimentin.&#xd;
Z-ajoene interacts with Vimentin through a S–thiolation causing the disruption of Vimentin&#xd;
filaments and therefore an alteration of the cell morphology. Given that Vimentin is known to&#xd;
participate to the early stage of the metastatic process, I also investigated the potential effect of&#xd;
Z-ajoene at non-cytotoxic concentrations in a specific cell assay and found that it effectively&#xd;
inhibits cell migration, both in the absence and presence of a chemotactic agent. The metastatic&#xd;
inhibition induced by Z-ajoene seems caused by modification of several signaling pathways as&#xd;
expression of Axl and Src proteins, and phosphorylation of β–catenin were changed. Although&#xd;
following inhibition of cell migration, a reduction of Vimentin expression was to be expected,&#xd;
Z-ajoene treatment surprisingly induced an upregulation of Vimentin. We interpreted this result&#xd;
as a consequence of Z-ajoene binding to Vimentin which unable this protein to perform its&#xd;
physiologic functions (manuscripts in preparation).&#xd;
Altogether, the data of my in vitro study indicate that Z-ajoene is a promising chemotherapeutic&#xd;
agent simultaneously acting on different molecular targets, also able to affect the metastatic&#xd;
process in cells derived from highly invasive breast tumors. Due to its potential use in the clinic,&#xd;
preclinical evaluation in xenograft mouse models of cancer are ongoing.</dc:description>
<dc:date>2016-03-23</dc:date>
<dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
<dc:identifier>http://hdl.handle.net/11584/266770</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>numberofpages:119</dc:relation>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:publisher>Università degli Studi di Cagliari</dc:publisher>
<dc:rights>license:Non specificato</dc:rights>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>